According to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a […]
(Reuters Health) – Women with obesity who undergo bariatric surgery may have a lower risk of breast cancer and get diagnosed at earlier stages when they do develop these malignancies, a recent meta-analysis and systematic review suggests. Researchers examined data from 11 studies with a total of 1,106,939 women with obesity, including 105,295 women (9.5%) […]
The genomic landscape of circulating tumor DNA (ctDNA) was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant prostate cancer (mCRPC), according to researchers. The type and frequency of genomic alterations observed were largely similar in ctDNA and tissue, and there was high concordance for BRCA1/2 alterations. Comprehensive […]
Endocrine therapy is standard of care for estrogen-receptor positive (ER+) breast cancer, but only about half of women respond. At present, there is no method for identifying the women who are likely — and also unlikely — to respond. But a new approach looks to be useful: it involves a trial of estrogen and then […]
MRNA VS. CONVENTIONAL VACCINES Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron Working Together to Empower Women Pfizer Women’s Resource Group Universal vs. Single Payer Healthcare Every year, World Cancer Day, an initiative led by the Union for International Cancer Control, is about taking action. The theme, “I Am and I Will,” charges us […]
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. EVIFYNE® V11219 Raloxifene hydrochloride Consumer Medicine Information What is in this leaflet This leaflet is designed to provide you with answers to some common questions about this medicine.It does not contain all the available information and does not take the place of […]
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APO-OLANZAPINE FILM COATED TABLETS Olanzapine Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about this medicine. It does not contain all the available information. It does not take the place of talking to your doctor or […]
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. PROVERA® Medroxyprogesterone acetate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about PROVERA.It does not contain all the available information.It does not take the place of talking to your doctor or pharmacist. All medicines have risks […]
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. FASLODEX® fulvestrant Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about FASLODEX. It does not contain all the information that is known about FASLODEX. It does not take the place of talking […]
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. IBRANCE® Palbociclib Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about IBRANCE. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have […]
